Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 92%
filed 2026-08-17
Item 8.01
Pluri's indirect subsidiary Ever After Foods entered into a share purchase agreement to acquire all outstanding share capital of Fishway BV in exchange for equity issuance, with concurrent $2.0 million SAFE investment. This constitutes a material acquisition that will reduce Pluri's indirect ownership in EAF from approximately 69% to 58%, representing a significant capital deployment and dilution event affecting the registrant's financial position and strategic direction.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-17
The 6-K discloses results of an Annual and Special General Meeting of Shareholders held on August 17, 2026, where shareholders voted on and approved seven proposals including auditor re-appointment, director re-elections, and executive compensation arrangements. This is a direct disclosure of shareholder vote results under Item 5.07 equivalent, covering material governance and compensation matters.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-08-17
EX-99.1
The press release announces Skyline Builders Group Holding's acquisition of two mineral properties (Mill Creek Project and Irwin Project) in Nevada. This constitutes a material acquisition of assets. Additionally, the disclosure emphasizes the pending transformative business combination with Cove Kaz Resources expected to close by year-end or early 2027, which is a material merger/change of control event. The Nevada acquisitions are explicitly framed as diversifying the company's portfolio ahead of this transformative combination.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
The 8-K discloses under Item 2.02 the Company's financial results for Q2 2026 ended June 30, 2026, with a press release attached as Exhibit 99.1. The press release reports Q2 revenue of $0.7 million (up 36.5% YoY), gross profit of $0.3 million (up 86.6% YoY), and gross margin expansion to 41.7% from 30.5%, along with operational highlights including state-funded firefighter screening programs and cash position strengthening to $4.5 million. This is a standard quarterly earnings disclosure material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-17
The filing discloses entry into a definitive merger agreement on June 25, 2026, whereby ENDRA will merge with Noble Africa LLC (a subsidiary of ASP Isotopes Inc.), with ENDRA to be renamed Noble Africa Inc. and the company to pursue Renergen's Virginia Gas Project. This is a material change of control transaction with expected closing in Q4 2026, accompanied by a $50 million private placement. While the press release also reports Q2 2026 financial results (Item 2.02), the central disclosed event is the merger agreement, making ma_activity the primary classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-17
Item 5.07
Silo Pharma held its annual shareholder meeting on August 14, 2026, with voting results on four proposals: election of four directors (all approved), ratification of Salberg & Company as auditor (approved), authorization to increase authorized common shares from 6.67 million to 250 million shares (approved with 498,224 votes for and 190,599 against), and meeting adjournment authority (approved). The substantial increase in authorized shares represents a material expansion of the company's equity issuance capacity and potential dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-17
Turn Therapeutics entered into securities purchase agreements on August 14, 2026 to issue and sell 135,000 shares of common stock at $10.00 per share for $1.35 million aggregate gross proceeds in a private placement relying on Section 4(a)(2) and Regulation D exemptions. This is a classic unregistered equity issuance to accredited investors that dilutes existing shareholders and raises capital, fitting the dilutive_issuance category. The company also granted registration rights to the investors, further evidencing the nature of this transaction.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-17
The 6-K discloses entry into a material definitive agreement on August 14, 2026, whereby Happy City Holdings agreed to acquire 100% of Wing Shing International Consultancy Limited for 1,312,487 Class A Ordinary Shares valued at US$2,598,726. The acquisition represents a strategic expansion into B2B and corporate catering services and will result in the Consideration Shares representing approximately 6.9% of the Company's enlarged issued share capital, meeting the materiality threshold for M&A activity under Item 1.01.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-08-17
Item 8.01
This disclosure concerns a one-month extension of Ribbon Acquisition Corp.'s deadline to consummate an initial business combination, funded by a $125,000 deposit into the trust account on August 11, 2026. The extension moves the deadline from August 15 to September 15, 2026. This is a governance/structural matter affecting the SPAC's timeline and shareholder rights, and is material because it directly impacts the registrant's ability to complete its stated business purpose and affects the liquidity and redemption rights of public shareholders.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 85%
filed 2026-08-17
EX-99.1
Zhibao Technology Inc. disclosed a form executive employment agreement establishing material compensatory arrangements for an executive officer, including cash compensation, equity incentives, benefits, and severance/termination provisions.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-17
Item 2.02
QDM International Inc. issued a press release on August 17, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing revenue of $8.4 million (up 133.4% year-over-year), net income of $3.2 million (up 70.2%), and basic EPS of $0.36 (up from $0.22), along with condensed consolidated financial statements.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-17
Akanda Corp. received a Nasdaq deficiency letter on June 16, 2026, for failing to maintain the minimum $2.5 million stockholders' equity required under Nasdaq Listing Rule 5550(b)(1). Although Nasdaq granted an extension through December 13, 2026, the filing explicitly states "The Company's failure to meet these requirements could result in the Company's securities being delisted from Nasdaq." This is a clear delisting risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-17
Item 1.01
Singularity Future Technology entered into a securities purchase agreement to sell 21,520,803 shares of common stock at $1.394 per share for approximately $30 million in a private placement to non-U.S. persons under Regulation S. This unregistered equity issuance will significantly dilute existing shareholders and represents a material capital-raising event.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 85%
filed 2026-08-17
The 6-K discloses the issuance of $125 million in 7.50% Senior Unsecured Convertible Notes due 2031, completed on July 17, 2026. Although the filing itself is primarily an explanatory notice regarding registration of the Notes and distribution of a prospectus supplement, the underlying event — creation of a material direct financial obligation — is a debt issuance. The convertible feature does not change the classification; the primary obligation is debt. The amount and terms are material to investors.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-17
Item 3.01
Helix Acquisition Corp. III received a written notice from Nasdaq on August 14, 2026, indicating non-compliance with Listing Rule 5452(a)(2)(A) regarding the Minimum Total Holders Requirement (at least 300 total holders). Although the notice is characterized as a deficiency notification rather than imminent delisting, the Company has 45 calendar days to submit a compliance plan or face potential delisting proceedings. This is a classic delisting-risk disclosure under Item 3.01, material to investors as it threatens continued listing on Nasdaq Global Market.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-17
Item 7.01
This Item 7.01 disclosure furnishes an investor presentation covering New Era's Q2 2026 business update, including material operational milestones: receipt of construction permits for the Texas Critical Data Centers (TCDC) project, increased Phase 1 & 2 capacity to ~757 MW, advanced PPA negotiations, and leadership appointments. While the filing includes multiple operational and governance elements (executive appointments, funding strategy, permitting progress), the central disclosed event is the company's operational and strategic progress on its flagship TCDC development project, which does not fit a specific named category but is clearly material and operational in nature.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-08-17
EX-99.2
Gauzy Ltd. is soliciting shareholder votes on a proposal to authorize the Board to effect reverse share splits at ratios ranging from 1-for-2 to 1-for-1,000 and related amendments to the Company's Memorandum and Articles of Association at a Special General Meeting scheduled for August 31, 2026.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-17
EX-99.1
ArcelorMittal discloses a missile strike on its Ukraine plant (ArcelorMittal Kryvih Rih) resulting in two employee deaths, 13 injuries, and significant damage to main production facilities including energy and blast furnace production, with partial halting of production processes. This is a material operational and safety event affecting a major production asset, though it does not fit the specific categories of workforce_reduction (no announced layoffs), material_litigation, or other named types. The disclosure is clearly operational in nature—a geopolitical incident materially impacting production capacity and operations.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-17
EX-99.1
The news release announces the filing of a preliminary economic assessment (PEA) technical report for the Carangas Project in Bolivia, prepared by Ausenco Engineering in accordance with NI 43-101 standards. This is a material operational/strategic milestone for an exploration and development company advancing precious metals projects, as the PEA provides independent technical and economic evaluation of the project's viability and potential, which would inform investor assessment of the company's asset value and development prospects.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-17
EX-99.1
DEFSEC announced a private placement of 1,951,219 common shares (or pre-funded warrants in lieu) at CAD$2.84 per share, plus common share purchase warrants, generating approximately CDN$5.54 million in gross proceeds. The securities are unregistered under the U.S. Securities Act and being sold pursuant to an exemption, with a registration rights agreement for future resale. This is a classic dilutive equity issuance that would materially affect shareholder ownership and is a strong signal of capital-raising activity typical of small- and mid-cap issuers.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-08-17
EX-99.1
OceanaGold has entered into a definitive scheme implementation deed to acquire 100% of Ausgold Limited for approximately A$776M (US$549M) in an all-stock transaction (0.03365 OceanaGold shares per Ausgold share, with a cash alternative up to A$194M). This is a material acquisition of a development-stage gold project (Katanning) that will add a fifth asset to OceanaGold's portfolio and is expected to add 100,000+ ounces of annual production. The transaction is subject to customary closing conditions and Ausgold shareholder approval, with implementation expected in December 2026.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-17
The 6-K furnishes a "Consolidated Synthetic remote voting map" disclosing the results of an Extraordinary General Meeting held on August 18, 2026. The document presents voting tallies on seven items including the number of Board members, nomination and election of directors (Daniel Barriuso Rojo and Gilson Finkelsztain), and confirmation of Board composition. This is a direct disclosure of shareholder vote results as required by CVM Resolution No. 81/22, matching the `shareholder_vote_results` taxonomy type.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-17
Item 1.01
Fabrinet's Thai subsidiary entered into a term loan agreement for THB 2.50 billion (~$75 million) under an amended credit facility, with the facility increased to THB 2.61 billion (~$78.3 million) plus $100 million, guaranteed by the parent company and used for capital expenditures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-17
Item 2.02
Fabrinet issued a press release on August 17, 2026 disclosing financial results for the fourth quarter and fiscal year ended June 26, 2026, including record quarterly revenue of $1.316 billion (45% YoY growth) and record fiscal year revenue of $4.6 billion (36% YoY growth), along with forward guidance for Q1 FY2027.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-08-17
Item 5.02
Fabrinet adopted a fiscal 2027 Cash Bonus Plan for named executive officers, approved base salary increases ranging 6.7% to 11.1%, and granted equity awards of RSUs, PSUs, and Stretch PSUs totaling $30 million across four executives with specified performance metrics and vesting schedules.
View raw filing on EDGAR →
8-K
Earnings release
confidence 90%
filed 2026-08-17
Item 2.02
QumulusAI disclosed preliminary financial results for Q2 2026, including cash of approximately $19.97 million and gross profit figures for the three and six-month periods ended June 30, 2026. The company announced its intention to report full second quarter 2026 financial results on August 25, 2026, and host a conference call to discuss results, marking the company's first quarterly results call as a public company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
Item 2.02
This is a straightforward earnings release disclosing Q2 2026 financial results for Nuo Therapeutics. The filing explicitly states "On August 17, 2026, Nuo Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2026" under Item 2.02. The press release includes consolidated balance sheets and statements of operations showing revenue of $1.77M (Q2) and $3.07M (H1 2026), both up over 150% year-over-year, along with operational metrics and business updates. This is material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-08-17
Item 7.01
The Company posted Q2 2026 financial information on its Investor Relations website and furnished a presentation as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). While technically a Reg FD disclosure rather than a formal earnings release, the substance is disclosure of quarterly financial results to investors, which is material to a reasonable investor's assessment of the registrant's financial performance and condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
Item 2.02
NRx Pharmaceuticals disclosed its second quarter 2026 financial results via press release on August 17, 2026, as required under Item 2.02. The filing reports net loss of $18.0 million for the six months ended June 30, 2026 (versus $23.1 million in the prior year), net operating loss of $11.3 million, and cash position of $26.7 million as of June 30, 2026. The press release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-17
Item 2.02
Blue Dolphin Energy Company disclosed its quarterly and six-month financial results for the period ended June 30, 2026 via a press release attached as Exhibit 99.1. The disclosure includes net income of $17.7 million ($1.19 per share) for Q2 2026 and $32.5 million ($2.18 per share) for the six-month period, along with gross profit, EBITDA, and liquidity metrics. This is a standard earnings release filed under Item 2.02 and represents material financial results that would affect a reasonable investor's assessment of the company's performance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-17
Item 8.01
Gray Media announced the commencement of a $750 million offering of senior secured first lien notes due 2034, a material creation of new direct financial obligations. The proceeds will be used to redeem $675 million of existing 2029 Notes, repay revolving credit facility borrowings, and pay transaction fees. This is a significant debt refinancing and capital structure event material to investors.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-17
Item 8.01
The filing discloses settlement of material litigation with Puritan Partners LLC that had been pending since November 2023 and "hindered our ability to raise capital and pursue strategic opportunities." The settlement involves exchange of existing debt instruments for new $2.35 million senior secured convertible notes maturing in February 2028. This is a material litigation settlement that removes a significant constraint on the company's operations and capital access, making it material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
The Board elected Ret. Lt. Gen. Sean Gainey to serve on the Board and its Nominating and Corporate Governance Committee on August 13, 2026. This is a clear appointment of a director to the Board, which is a material governance event affecting the composition of the registrant's leadership. The disclosure includes his background, compensation arrangements, and standard indemnification agreement, all consistent with a director appointment disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-17
Item 5.02
Constantine Petropoulos was appointed Senior Vice President and Chief Financial Officer effective August 12, 2026. While the disclosure also includes a compensatory arrangement (salary increase from $357,000 to $425,000 and a stock option grant of 25,000 shares), the principal disclosed action is the appointment of an executive to a material C-suite role (CFO). The appointment of a CFO is a significant governance event affecting investor assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-17
Item 7.01
This Item 7.01 disclosure furnishes a 2026 Shareholder Letter providing strategic and operational updates on the company's progress, including the completed Flipside AI acquisition, new executive appointments, commercial engagements with major AI/robotics customers, and plans for platform development and Nasdaq uplisting. While the letter touches on multiple domains (M&A, governance, operations, capital-raising), the core disclosure is a comprehensive operational and strategic update rather than a discrete material event. The acquisition itself (completed April 1, 2026) would have been reported separately; this letter contextualizes it alongside ongoing business development and future strategy, making it primarily an operational disclosure of material significance to investors assessing the company's trajectory.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Jonathan Gutoski was appointed Chief Financial Officer of Edible Garden AG effective August 17, 2026, replacing Kostas Dafoulas who resigned as Interim CFO on August 14, 2026. While the section discloses both a departure and an appointment, the principal disclosed action centers on the appointment of a named executive officer to a key financial leadership role. The disclosure includes Gutoski's background, compensation ($220,000 base salary plus $10,000 signing bonus and up to 25% discretionary bonus), and confirms no related-party arrangements or conflicts of interest.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 65%
filed 2026-08-17
Item 1.01
The Company entered into a Non-Employee Director Agreement with Ximing Huang, formalizing his three-year term as Chairman and CEO. The agreement establishes his executive role and governance position within the Company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-17
Item 3.02
The Company issued one share of Series B Preferred Stock to Ximing Huang in an unregistered offering relying on Section 4(a)(2) exemption. The preferred stock carries material voting and economic rights, representing a significant capital structure change.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-17
Item 3.03
The Company implemented a dual-class capital structure through Series B Preferred Stock held by Ximing Huang, granting him 51% voting power and 83.1% total voting control. This material modification to security holder rights concentrates voting control and may affect minority shareholder influence and market inclusion.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-17
EX-99.5
This is a news release dated August 17, 2026, announcing Santacruz Silver Mining's second quarter 2026 financial results. The document discloses Q2 2026 revenues of $113.5 million (55% YoY increase), gross profit of $51.1 million (102% YoY increase), adjusted EBITDA of $46.7 million (74% YoY increase), and net income of $2.0 million. It includes detailed operational and financial highlights, reconciliation tables, and management commentary on performance drivers. This is a classic earnings release announcing quarterly financial results, material to investors assessing the company's financial performance and operational trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-17
EX-99.1
Pulsenmore announced receipt of a $1.27 million grant from the Israel Innovation Authority for its SmartScan AI program, bringing total AI grants approved within one month to approximately $1.6 million. This is a material operational and strategic development—the company is advancing its core product roadmap (AI-powered home ultrasound) with external validation and funding support. While not a discrete M&A, financing, or governance event, the grant represents a significant operational milestone that would affect a reasonable investor's assessment of the company's technology development trajectory and strategic positioning in AI-enhanced ultrasound.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
The 8-K discloses Item 2.02 (Results of Operations and Financial Condition) with a press release announcing InspireMD's financial and operating results for the three and six months ended June 30, 2026. The filing includes detailed quarterly revenue ($1.8M Q2 2026), gross loss/profit metrics, operating expenses, net loss ($14.3M Q2, $28.0M six months), and per-share results, along with business highlights including product recalls, clinical trial outcomes, and cost-reduction initiatives. This is a standard earnings release disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-17
Item 7.01
AmpliTech disclosed a business and financial outlook update following an amendment to its Titan Crest Asset Purchase Agreement, highlighting $17 million in backlog, improved margin expectations beginning in 2027, and a path to positive EBITDA in FY2027. While the disclosure includes forward-looking financial guidance, it centers on operational strategy and market positioning in the Open RAN 5G segment rather than a discrete financial event (earnings release, debt issuance, or impairment). The amendment itself reduced the purchase price by $1 million and preserved the company's rights, representing a material operational development affecting the company's ORAN business execution and financial trajectory.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-17
Fast Track Group received a Staff Determination letter from Nasdaq on August 11, 2026, notifying the Company of its determination to delist the Company's securities from The Nasdaq Capital Market due to failure to maintain a minimum bid price of $1.00 or higher under Listing Rule 5550(a)(2). Trading suspension is scheduled for August 18, 2026, with the Company intending to appeal and request a hearing before a Hearings Panel. This is a clear delisting risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-17
The filing discloses results of a Special Meeting of stockholders held on August 13, 2026, where shareholders voted on a Charter Amendment Proposal to extend the Business Combination Period by nine months (from August 18, 2026 to May 18, 2027). The proposal received 3,904,200 affirmative votes representing 96.1% of outstanding shares, exceeding the 65% approval threshold required. Item 5.07 explicitly reports submission of matters to a vote of security holders and the voting results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-17
The 8-K discloses NexGel's second quarter 2026 financial results under Item 2.02, with a press release attached as Exhibit 99.1. The filing reports Q2 revenue of $3.69 million and a net loss of $2.87 million for the period ending June 30, 2026, along with operational updates regarding the Celularity acquisition integration and strategic initiatives. This is a standard quarterly earnings release material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-17
The filing discloses entry into a securities purchase agreement on August 15, 2026, whereby the Company issued a secured promissory note of $6.5 million initially with additional tranches up to $10 million aggregate to Bower Family Holdings, LLC. This is a creation of a new direct financial obligation under Item 1.01 and Item 2.03, with a 10% annual interest rate and 24-month term. The proceeds are used for working capital and repayment of existing convertible debt, representing a material debt issuance event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-17
The filing discloses a private placement of 933,064 shares of common stock, 1,360,544 pre-funded warrants, and 4,587,216 series E and F warrants in an unregistered offering under Section 4(a)(2) and Regulation D. The transaction raises approximately $3.4 million in gross proceeds with potential additional proceeds of $6.7 million upon warrant exercise. Company insiders, including the CEO and CFO, participated in the offering, purchasing approximately $2.4 million of securities. This is a classic dilutive equity issuance by a small-cap company raising capital through warrants and pre-funded warrants.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-17
The 8-K discloses Item 2.02 (Results of Operations and Financial Condition) with a press release announcing Q2 2026 financial results for INVO Fertility. The filing reports revenue of $2.2 million (17% increase YoY), clinic-level Adjusted EBITDA profitability of $333,000, and net income of $0.9 million. This is a standard quarterly earnings release with detailed financial statements and management commentary, clearly material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-17
Item 3.02
Daré Bioscience announced a registered direct offering of 4,379,581 shares of common stock (or pre-funded warrants) at $1.37 per share, generating $6.0 million in gross proceeds, plus concurrent private placement of Series A and Series B warrants. The press release explicitly states the Series A and Series B warrants are being offered under Section 4(a)(2) of the Securities Act and Regulation D as an unregistered private placement. This is a classic dilutive equity issuance combining registered and unregistered securities to raise capital.
View raw filing on EDGAR →